Welcome to the latest edition of European Neurological Review, which features a wide range of articles of interest to neurologists and other practitioners involved in the care of patients with neurological illness. As we move into a new decade, the field of neurology continues to face fresh challenges. Despite an increased understanding of the pathophysiological processes underlying neurological illness, the burden of neurological disease is growing in our ageing population.
We begin with an expert interview, in which Najib Khalife describes the recent developments in therapeutic plasma exchange and its immunomodulatory effects in neuromuscular diseases. Next, in an editorial, Uwe Reuter discusses the latest clinical data in support of erenumab, which is proving highly effective in patients with difficult-to-treat migraine who have high unmet needs and few treatment options. In another editorial, Leong Tung Ong describes the pathogenesis underlying temporal lobe epilepsy.
The optimal treatment of myasthenia gravis is challenging, particularly in elderly patients who have comorbid conditions. Nils Erik Gilhus reviews the current treatment options for patients with severe disease. Multiple sclerosis (MS) also presents a therapeutic challenge, particularly given the increasing number of approved MS therapies and their various associated side effects. Beyza Ciftci-Kavaklioglu and E Ann Yeh present a comprehensive review of an emerging therapy – the small molecule sphingosine-1-phosphate receptor modulator, ozanimod – which appears promising in early stage clinical trials and offers the potential of reduced cardiac effects compared to its predecessor, fingolimod.
Published alongside this edition, we have two sponsored supplements, both summarising the proceedings of satellite symposia held at the 5th Congress of the European Academy of Neurology, Oslo, Norway, on the subject of Parkinson’s disease (PD). In the first, Poewe et al. discuss the challenge of treatment responses wearing-off in patients with PD, as well as the importance of early detection of wearing-off, and current management strategies to lessen its impact. In the second, Pagonabarraga et al. describe strategies to optimise dopamine treatments, which remain the gold-standard therapy for PD, including combined treatment strategies and alternative pharmacological approaches.
We would like to end with an invitation to authors to submit review articles, editorials, special reports, case reports and original research across all areas of neurology. We are particularly interested in the submission of real-world studies and topical review articles that provide a concise overview of the latest clinical trial data and developments in the field. Authors can submit their manuscript directly through the Editorial Manager site (details below) and presubmission enquiries can be made to the journal’s editor, christina.mackins@touchmedicalmedia.com. Accepted articles are published free-to-access online, and we encourage authors to submit accompanying multimedia content alongside their article.
European Neurological Review would like to wish our readers a happy and successful 2020. Thanks to all expert authors who contributed towards this edition. We are grateful to our Editorial Board for their constant guidance. Thanks also go to all society partners, associations and key congresses for their ongoing support. We look forward to collaborating with you over the next year and hope that European Neurological Review continues to fulfil its useful role within the medical community.
Cris S Constantinescu and the European Neurological Review team
Submissions Website: www.editorialmanager.com/touchneuro/default.aspx
Contact the Editor: christina.mackins@touchmedicalmedia.com
About the Journal: https://touchneurology.com/about-us/
Instructions for Authors: https://touchneurology.com/neurology-journals/
Citation: European Neurological Review. 2019;14(2):60
Cris S Constantinescu
Cris Constantinescu is Professor of Neurology in the Division of Clinical Neurosciences at the University of Nottingham, UK. He graduated with an MD from Boston University School of Medicine in 1988. As recipient of the physician-scientist award from the National Institutes of Health, USA, he completed a PhD in immunology at the University of Pennsylvania in 1998. He completed an internship, a residency in neurology and fellowships in neuroimmunology and neurorehabilitation. He was appointed honorary consultant neurologist and senior lecturer in neurology at the University of Nottingham in 2000–2001. In 2004, he was appointed Professor of Neurology and Chair in Neurology at the University of Nottingham. He has authored or co-authored over 170 articles in international journals. His research interests are immune regulation in inflammatory diseases of the nervous system, in particular multiple sclerosis (MS) and its models, imaging in MS,
clinical trials and epidemiology. He runs a large, busy MS clinic, together with seven other clinical neurologists in Nottingham. He is the clinical lead for neurological diseases in the East Midlands Clinical Research Network.
